Affordable Access

deepdyve-link
Publisher Website

Managing diabetic macular edema: The leading cause of diabetes blindness.

Authors
  • Romero-Aroca, Pedro
Type
Published Article
Journal
World Journal of Diabetes
Publisher
Baishideng Publishing Group Co (World Journal of Diabetes)
Publication Date
Jun 15, 2011
Volume
2
Issue
6
Pages
98–104
Identifiers
DOI: 10.4239/wjd.v2.i6.98
PMID: 21860693
Source
Medline
Keywords
License
Unknown

Abstract

Diabetic macular edema (DME) is the leading cause of blindness in young adults in developed countries, affecting 12% of type 1 and 28% of type 2 diabetic patients. The gold standard DME treatment should be based on a good control of glycemia along with control of lipids and renal function. However, despite the systemic metabolic control values being essential for patients with diabetic retinopathy (DR), it has proven to be insufficient for DME if it appears. With these patients, additional measures are needed in order to avoid the subsequent loss of vision. While laser treatment of DME has been the only valid treatment so far, it has been inadequate in chronic cases. The introduction of new treatments, such as intravitreal corticosteroids or anti-VEGF drugs, have recently shown their safety and efficacy and together with laser photocoagulation are becoming the treatments of choice in the management of DME.

Report this publication

Statistics

Seen <100 times